非霍奇金淋巴瘤患者P-gp、P26-bcl-2表达的临床研究

目的：探讨多药耐药基因mdr-1及其蛋白P-gp,凋亡抑制基因bcl-2及其相关蛋白P26－bcl-2在中,高度恶性非霍奇金淋巴瘤（NHL）患者中表达的临床意义及潜在的预后价值,方法：应用免疫组织化学S－P法对60例NHL患者进行检测,结果,60例患者中P-gp表达中P－gp表达阳性者15例,P26－bcl-2表达阳性者25例,P-gp和P26－bcl-2共同表达为性者的3年生存率明显高于阳性表达者（分别为48．48％和15．38％,P＝0．038）,结论：P－gp,P26-bcl-2表达与中,高度恶性NHL患者的疗效果及预后相关,P－gp和P26－bcl-2共同表达情况可作为预测中,高度恶性NHL患者化疗敏感性及预后的指标。

Clinical study of P-gp,and bcl-2 protein expression in non-Hodgkin's lymphomas patients

Objective To investigate the relationship between the expression of P gp, P26 bcl 2 and the prognosis in intermediate and high grade non Hodgkin's lymphomas(NHL). Methods Sixty cases of intermediate and high grade NHL were retrospectively reviewed using immunohistochemical method. All patients were received CHOP chemotherapy over 4 courses. Results P gp was identified in 15 and P26 bcl 2 in 25 cases. The 3 year survival rates for patients with P26 bcl 2( ) and P26 bcl 2(-) were 37.64% and 76.80%, respectively (P<0.005), and for patients with both positive P gp and P26 bcl 2 and both negative were 15.38% and 48.48%,respectively (P=0.038). Conclusions There is direct relationship between the P gp, P26 bcl 2 protein expression and the prognosis in intermediate and high grade non Hodgkin's lymphoma.